Login to Your Account



Clinic Roundup


Friday, October 21, 2011
• Unigene Laboratories Inc., of Boonton, N.J., said all patients have completed the course of therapy in its Phase II study of an oral parathyroid hormone analogue in osteoporosis in postmenopausal women. Top-line data are anticipated by year-end. The drug is being developed in collaboration with London-based GlaxoSmithKline plc.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription